

=&gt; d que 157

L1	25646	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"B CELL (LYMPHOCYTE) "+OLD,NT/C
		T			
L2	585	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"B CELL (LYMPHOCYTE) (L)
		DISEASE"+OLD/CT			
L3	89634	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"T CELL (LYMPHOCYTE) "+OLD,NT/C
		T			
L4	2317	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"T CELL (LYMPHOCYTE) (L)
		DISEASE"+OLD/CT			
L5	11390	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	MAST CELL+OLD,NT/CT
L6	1116	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"LYMPHOCYTE (L) PLASMA
		CELL"+OLD/CT			
L7	6586	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	MULTIPLE MYELOMA+OLD/CT
L8	98	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"LEUKEMIA (L) PLASMA CELL"/CT
L9	17792	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	MYELOID
L10	231677	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	ANTIBODIES+OLD,NT/CT
L11	922	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"DRUG DELIVERY SYSTEMS (L)
		IMMUNOCONJUGATES"+OLD/CT			
L12	167382	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	CYTOKINES+OLD,NT/CT
L13	10258	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	IMMUNOTHERAPY+OLD,NT/CT
L14	25	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	NAKED (3A) ANTIBOD?
L15	14807	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	RIBONUCLEASE/CT
L16	138591	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L1 OR L2 OR L3 OR L4 OR L5
		OR L6 OR L7 OR L8 OR L9)			
L20	974	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	DOMESTIC ANIMAL+OLD/CT
L21	10768	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"DOG (CANIS FAMILIARIS) "+OLD,N
		T/CT			
L22	4942	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"CAT (FELIS CATUS) "+OLD,NT/CT
L23	865	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	FELIDAE+OLD/CT
L24	9287	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"HORSE (EQUUS CABALLUS) "+OLD,N
		T/CT			
L25	23476	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	(L20 OR L21 OR L22 OR L23 OR
		L24)			
L27	7507	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"CD4 (ANTIGEN) "+OLD,NT/CT
L28	861	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"CD5 (ANTIGEN) "+OLD/CT
L29	3780	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"CD8 (ANTIGEN) "+OLD/CT
L30	1764	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"CD14 (ANTIGEN) "+OLD,NT/CT
L31	266	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"ANTIGENS (L) SSEA-1 (STAGE-SP
		ECIFIC EMBRYONIC ANTIGEN			1) "+OLD/CT
L32	978	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"BLOOD-GROUP SUBSTANCES (L)
		LEX"/CT			
L33	899	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"CD19 (ANTIGEN) "+OLD/CT
L34	727	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"CD20 (ANTIGEN) "+OLD/CT
L35	620	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"COMPLEMENT RECEPTORS (L)
		TYPE 2"+OLD/CT			
L36	435	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"CD22 (ANTIGEN) "+OLD/CT
L37	6932	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	INTERLEUKIN 2 RECEPTORS+OLD/CT
L38	1585	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"INTERLEUKIN 2 RECEPTORS (L)
		.ALPHA.-CHAIN"+OLD/CT			
L39	380	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"CD ANTIGENS (L) CD33"+OLD/CT
L40	689	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"CD38 (ANTIGEN) "+OLD/CT
L41	126	SEA FILE=HCAPLUS	ABB=ON	PLU=ON	"CD ANTIGENS (L) CD52"+OLD/CT

L42 8115 SEA FILE=HCAPLUS ABB=ON PLU=ON "CELL ADHESION MOLECULES (L)  
ICAM-1 (INTERCELLULAR ADHESION MOL. 1)" +OLD/CT

L43 3349 SEA FILE=HCAPLUS ABB=ON PLU=ON "INVARIANT CHAIN (CLASS II  
ANTIGEN)" +OLD,NT/CT

L44 202 SEA FILE=HCAPLUS ABB=ON PLU=ON "GENE, ANIMAL (L) MUC1"/CT

L45 1432 SEA FILE=HCAPLUS ABB=ON PLU=ON "HISTOCOMPATIBILITY ANTIGENS  
(L) IA (H-2 I-REGION-ASSOCD.)" +OLD/CT

L46 4952 SEA FILE=HCAPLUS ABB=ON PLU=ON "HISTOCOMPATIBILITY ANTIGENS  
(L) HLA-DR" +OLD/CT

L47 3383 SEA FILE=HCAPLUS ABB=ON PLU=ON (L27 OR L28 OR L29 OR L30 OR  
L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR  
L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR L46) (L) ANTIBOD?

L48 395439 SEA FILE=HCAPLUS ABB=ON PLU=ON L10 OR L14 OR L11 OR L12 OR  
L15 OR L47

L49 59807 SEA FILE=HCAPLUS ABB=ON PLU=ON L16 AND L48

L50 2263 SEA FILE=HCAPLUS ABB=ON PLU=ON L49 AND L13

L51 125881 SEA FILE=HCAPLUS ABB=ON PLU=ON NEOPLASM+OLD/CT

L52 162735 SEA FILE=HCAPLUS ABB=ON PLU=ON ANTITUMOR AGENTS+OLD/CT

L53 273065 SEA FILE=HCAPLUS ABB=ON PLU=ON L51 OR L52

L54 1102 SEA FILE=HCAPLUS ABB=ON PLU=ON L50 AND L53

L55 11 SEA FILE=HCAPLUS ABB=ON PLU=ON L54 AND L25

L56 20 SEA FILE=HCAPLUS ABB=ON PLU=ON L16 AND L48 AND L13 AND L25

L57 20 SEA FILE=HCAPLUS ABB=ON PLU=ON L55 OR L56

=> d 157 ibib ab hitind 1-20

L57 ANSWER 1 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:719500 HCAPLUS

DOCUMENT NUMBER: 139:244702

TITLE: Anti-protozoal vaccines comprising immunogenic  
fragments of hypoxanthine guanine xanthine  
phosphoribosyl transferase and B cell epitopes

INVENTOR(S): Makobongo, Morris; Riding, George Alfred; Willadsen,  
Peter; Good, Michael

PATENT ASSIGNEE(S): The Council of the Queensland Institute of Medical  
Research, Australia

SOURCE: PCT Int. Appl., 66 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074543	A1	20030912	WO 2003-AU246	20030228
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,			

NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

AU 2002-845

A 20020301

AB Immunotherapy of protozoal diseases is provided by use of hypoxanthine guanine xanthine phosphoribosyl transferase protein, or peptide fragments thereof, as an immunogen in vaccines effective against protozoal diseases such as malaria and babesiasis. In particular, immunization with hypoxanthine guanine xanthine phosphoribosyl transferase or peptide fragments thereof, induces T cell immunity to blood stage malaria. In particular embodiments, the invention provides protein and DNA malaria vaccines and methods of prophylactic and therapeutic immunization that elicit T cell-mediated immune responses broadly applicable to protozoal diseases including malaria.

IC ICM C07H021-02

ICS C07H021-04; C12N005-06; C12N005-08; C07K014-445; C07K014-44;  
C07K016-20; A61K031-7105; A61K031-711; A61K038-10; A61K038-45;  
A61K039-015; A61K039-018; A61P033-06

CC 15-2 (Immunochemistry)

Section cross-reference(s): 63

IT **B cell (lymphocyte)**

**T cell (lymphocyte)**

(epitope; immunogenic fragments of hypoxanthine guanine xanthine phosphoribosyl transferase and B cell epitopes for use as vaccines against malaria and babesiasis)

IT Anaplasma

Animal

Babesia

Babesia bigemina

Babesia bovis

Babesia canis

Babesia divergens

Babesia microtia

**CD4-positive T cell**

Cattle

Chicken (Gallus domesticus)

Coccidiosis

DNA sequences

**Dog (Canis familiaris)**

Eimeria tenella

Epitopes

Giardia lamblia

Human

**Immunotherapy**

Leishmania braziliensis

Leishmania donovani

Leishmania mexicana

Leishmania tropica

Mammalia

Mouse

Plasmodium (malarial genus)

Plasmodium berghei yoelii

Protein sequences

Protozoa

Toxoplasma gondii

Trypanosoma congolense

Trypanosoma cruzi

Trypanosoma gambiense

**Vaccines**

(immunogenic fragments of hypoxanthine guanine xanthine phosphoribosyl transferase and B cell epitopes for use as vaccines against malaria and babesiasis)

**IT Cytokines****Interleukin 2**

Tumor necrosis factors

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(immunogenic fragments of hypoxanthine guanine xanthine phosphoribosyl transferase and B cell epitopes for use as vaccines against malaria and babesiasis)

**IT Antibodies**

RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(immunogenic fragments of hypoxanthine guanine xanthine phosphoribosyl transferase and B cell epitopes for use as vaccines against malaria and babesiasis)

**IT Interferons**

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(.gamma.; immunogenic fragments of hypoxanthine guanine xanthine phosphoribosyl transferase and B cell epitopes for use as vaccines against malaria and babesiasis)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:656808 HCAPLUS

DOCUMENT NUMBER: 139:196278

TITLE: Anti-CD20 antibodies and fusion proteins for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases

INVENTOR(S): Hansen, Hans; Qu, Zhengxing; Goldenberg, David M.

PATENT ASSIGNEE(S): Immunomedics, Inc., USA; McCall, John Douglas

SOURCE: PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068821	A2	20030821	WO 2003-GB665	20030214
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,			

ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2002-356132P P 20020214

US 2002-416232P P 20021007

AB The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis.

IC ICM C07K016-28

ICS A61K039-395; C12N015-13; C12N005-10; G01N033-53

CC 15-3 (Immunochemistry)

Section cross-reference(s): 1, 3, 8, 9, 63

IT **Interleukins**

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(21; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antigens**

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CD126; humanized or chimeric monoclonal anti-**CD20 antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **CD antigens**

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**CD33**; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **CD antigens**

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**CD52**; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Immunoglobulins**

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(G1; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Immunoglobulins**

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(G; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Histocompatibility antigens**

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**HLA-DR**; humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

IT **Antigens**

- RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(HM1.24; humanized or chimeric monoclonal anti-**CD20 antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
- IT **Cell adhesion molecules**  
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(**ICAM-1 (intercellular adhesion mol. 1)**; humanized or chimeric monoclonal anti-**CD20 antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
- IT **Histocompatibility antigens**  
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(**Ia (H-2 I-region- assocd.)**; humanized or chimeric monoclonal anti-**CD20 antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
- IT **Antigens**  
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(**SSEA-1 (stage-specific embryonic antigen 1)**; humanized or chimeric monoclonal anti-**CD20 antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
- IT **Antibodies**  
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(bispecific; humanized or chimeric monoclonal anti-**CD20 antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
- IT **Antibodies**  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(chimeric; humanized or chimeric monoclonal anti-**CD20 antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
- IT **B cell (lymphocyte)**  
(**disease**; humanized or chimeric monoclonal anti-**CD20 antibodies** and conjugates for diagnosis and treatment of B cell **disease**, B cell malignancy and autoimmune diseases)
- IT **Immunoglobulins**  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(fragments; humanized or chimeric monoclonal anti-**CD20 antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
- IT **Immunoglobulins**  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(heavy chains; humanized or chimeric monoclonal anti-**CD20 antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell

- malignancy and autoimmune diseases)
- IT Alkylating agents, biological  
Angiogenesis inhibitors  
Antibiotics  
Autoimmune disease  
**B cell (lymphocyte)**  
Biomarkers (biological responses)  
**Cat (Felis catus)**  
Color formers  
Cytotoxic agents  
DNA sequences  
**Dog (Canis familiaris)**  
**Domestic animal**  
Drug delivery systems  
Drugs  
Dyes  
Epitopes  
Genetic vectors  
Human  
Imaging agents  
Immunomodulators  
**Immunotherapy**  
Labels  
**Lymphocyte**  
Lymphoma  
Mammalia  
Molecular cloning  
Mouse  
**Multiple myeloma**  
Myasthenia gravis  
Protein sequences  
Pseudomonas  
Rodentia  
Transplant rejection  
cDNA sequences  
(humanized or chimeric monoclonal anti-CD20 antibodies and conjugates  
for diagnosis and treatment of **B cell**  
**disease, B cell** malignancy and autoimmune  
diseases)
- IT **Antibodies**  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);  
DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL  
(Biological study); PREP (Preparation); USES (Uses)  
(humanized or chimeric monoclonal anti-CD20 antibodies and conjugates  
for diagnosis and treatment of B cell disease, B cell malignancy and  
autoimmune diseases)
- IT Abrins  
Alkaloids, biological studies  
Anthracyclines  
Antisense oligonucleotides  
**CD14 (antigen)**  
**CD19 (antigen)**  
**CD20 (antigen)**  
**CD22 (antigen)**  
**CD38 (antigen)**  
**CD4 (antigen)**  
CD40 (antigen)

CD5 (antigen)  
CD8 (antigen)  
CD80 (antigen)  
CD80 (antigen)  
**Cytokines**  
Enzymes, biological studies  
Fusion proteins (chimeric proteins)  
Hemopoietins  
Hormones, animal, biological studies  
**Interferons**  
**Interleukin 1**  
**Interleukin 10**  
**Interleukin 12**  
**Interleukin 18**  
**Interleukin 2**  
**Interleukin 3**  
**Interleukin 6**  
**Interleukins**  
**Invariant chain (class II antigen)**  
**Lymphotoxin**  
Oligonucleotides  
Radionuclides, biological studies  
Ricins  
Stem cell factor  
Tenascins  
Toxins  
Transforming proteins  
Tumor necrosis factors  
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(humanized or chimeric monoclonal anti-CD20 **antibodies** and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)  
IT **Antibodies**  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(humanized; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)  
IT **Drug delivery systems**  
(**immunoconjugates**; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)  
IT **Immunoglobulins**  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(light chains; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)  
IT **Antibodies**  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(monoclonal; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell



- malignancy and autoimmune diseases)
- IT **Complement receptors**  
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (type 2; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
- IT **Interleukin 2 receptors**  
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (.alpha.-chain; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
- IT **Interferons**  
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (.alpha.; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
- IT **Interferons**  
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (.beta.; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
- IT **Interferons**  
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (.gamma.; humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)
- IT 55-86-7, Nitrogen mustard 57-13-6D, Urea, substituted derivs. 59-30-3D, Folic acid, analogs 60-34-4D, Methylhydrazine, derivs. 120-73-0D, Purine, analogs 151-56-4D, Ethylenimine, derivs. 289-95-2D, Pyrimidine, analogs 1605-68-1D, Taxane, analogs 4375-07-9D, Epipodophyllotoxin, derivs. 7439-89-6, Iron, biological studies 7439-96-5, Manganese, biological studies 7440-06-4D, Platinum, coordination complexes 7440-54-2, Gadolinium, biological studies 7689-03-4D, Camptothecin, analogs 9001-99-4, Ribonuclease 9003-98-9, DNase I 9014-42-0, Thrombopoietin 10043-66-0, Iodine-131, biological studies 10098-91-6, Yttrium-90, biological studies 11096-26-7, Erythropoietin 13010-20-3D, Nitrosourea, derivs. 13981-22-1, Nitrogen-13, biological studies 13981-56-1, Fluorine-18, biological studies 13982-43-9, Oxygen-15, biological studies 14119-09-6, Gallium-67, biological studies 14158-30-6, Iodine-124, biological studies 14158-31-7, Iodine-125, biological studies 14265-75-9, Lutetium-177, biological studies 14265-85-1, Actinium-225, biological studies 14276-53-0, Copper-62, biological studies 14333-33-6, Carbon-11, biological studies 14378-26-8, Rhenium-188, biological studies 14391-73-2, Copper-66, biological studies 14596-37-3, Phosphorus-32, biological studies 14809-53-1, Yttrium-86, biological studies 14913-49-6, Bismuth-212, biological studies 14998-63-1, Rhenium-186, biological studies 15056-34-5D, Triazene, derivs. 15715-08-9, Iodine-123, biological studies 15750-15-9, Indium-111, biological studies 15755-39-2, Astatine-211, biological studies 15757-14-9, Gallium-68, biological studies 15757-86-5, Copper-67, biological studies 15765-38-5, Bromine-76, biological studies

15776-20-2, Bismuth-213, biological studies 23214-92-8D, Doxorubicin, analogs 33069-62-4D, Taxol, analogs 62683-29-8, Colony stimulating factor 75037-46-6, Gelonin 83869-56-1, GM-CSF 127464-60-2, Vascular endothelial growth factor 143011-72-7, G-CSF 187888-07-9D, Endostatin, analogs 352423-07-5, Placenta growth factor 378784-41-9, Technetium-94m, biological studies 378784-45-3, Technetium-99m, biological studies  
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (humanized or chimeric monoclonal anti-CD20 antibodies and conjugates for diagnosis and treatment of B cell disease, B cell malignancy and autoimmune diseases)

L57 ANSWER 3 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:488616 HCAPLUS

DOCUMENT NUMBER: 139:67777

TITLE: Generation of genetically modified vertebrate precursor lymphocytes for production of antibody, antigen receptor, heterologous binding protein or fragment

INVENTOR(S): Grawunder, Ulf; Melchers, Georg Friedrich

PATENT ASSIGNEE(S): Germany

SOURCE: Eur. Pat. Appl., 111 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1321477	A1	20030625	EP 2001-130805	20011222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2003068819	A1	20030821	WO 2001-EP15303	20011222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2001-130805 A 20011222

AB The present invention generally relates to the fields of genetic engineering and antibody prodn. In particular, it relates to the generation of genetically modified vertebrate precursor lymphocytes that have the potential to differentiate into more mature lymphoid lineage cells, and to the use thereof for the prodn. of any heterologous antibody or binding protein. Retroviral vector pLIB-bcl2-IRES-hygroB was constructed for overexpression of Bcl2 gene in murine. Long term proliferating murine precursor B cells with inactivated endogenous Ig. heavy and light chain gene loci were prepd. and used to generate human Ig.-producing murine precursor B cells.

IC ICM C07K016-00

ICS C12N005-20; C12N005-10; C12N005-06; A61K039-00

CC 15-3 (Immunochemistry)  
Section cross-reference(s): 3, 9

IT **Cytokines**  
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
(TNFSF7 (tumor necrosis factor superfamily member 7); generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **Antibodies**  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(bispecific; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **Antibodies**  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(chimeric; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **Immunoglobulins**  
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(fragments; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT Amphibia  
Aves  
    **B cell (lymphocyte)**  
Bacteria (Eubacteria)  
Bony fish (Osteichthyes)  
Cattle  
Chondrichthyes  
Chromosome  
DNA sequences  
Gene targeting  
Genetic markers  
Genetic vectors  
Gram-negative bacteria  
Guinea pig (*Cavia porcellus*)  
    **Horse (*Equus caballus*)**  
Human  
Hybridoma  
Immunization  
    **Immunotherapy**  
Lymphocyte  
Mammalia  
Mitogens  
Molecular cloning  
Mouse  
    **Multiple myeloma**  
Plasmids  
Rabbit  
Rat

Reptilia  
Retroviral vectors  
Rodentia  
Sheep  
Swine  
    **T cell (lymphocyte)**  
Transplant and Transplantation  
Vertebrata  
Viral vectors  
Yeast  
    (generation of genetically modified vertebrate precursor lymphocytes  
    for prodn. of antibody, antigen receptor, heterologous binding protein  
    or fragment)  
IT Antigen receptors  
    **Immunoglobulins**  
    RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);  
    DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP  
    (Preparation); USES (Uses)  
    (generation of genetically modified vertebrate precursor lymphocytes  
    for prodn. of antibody, antigen receptor, heterologous binding protein  
    or fragment)  
IT **CD19 (antigen)**  
    **CD20 (antigen)**  
    CD30 (antigen)  
    **CD38 (antigen)**  
    CD40 (antigen)  
    CD80 (antigen)  
    CD86 (antigen)  
    Fas antigen  
    Genetic element  
    Growth factors, animal  
        **Interleukin 10**  
        **Interleukin 13**  
        **Interleukin 2**  
        **Interleukin 4**  
        **Interleukin 5**  
        **Interleukin 6**  
    LFA-3 (antigen)  
    Lipopolysaccharides  
    Lipoproteins  
    Promoter (genetic element)  
    TCR (T cell receptors)  
    Transferrin receptors  
    RL: BSU (Biological study, unclassified); BUU (Biological use,  
    unclassified); BIOL (Biological study); USES (Uses)  
    (generation of genetically modified vertebrate precursor lymphocytes  
    for prodn. of **antibody**, antigen receptor, heterologous  
    binding protein or fragment)  
IT **Immunoglobulins**  
    RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);  
    DGN (Diagnostic use); REM (Removal or disposal); THU (Therapeutic use);  
    BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)  
    (heavy chains; generation of genetically modified vertebrate precursor  
    lymphocytes for prodn. of antibody, antigen receptor, heterologous  
    binding protein or fragment)  
IT **T cell (lymphocyte)**  
    (helper cell, antigen-primed; generation of genetically modified

vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **Antibodies**

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(heterologous; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **Antibodies**

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(humanized; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **Immunoglobulins**

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); REM (Removal or disposal); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(light chains; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **Antibodies**

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(monoclonal; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **Antibodies**

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(multiple specific; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

IT **Complement receptors**

Tumor necrosis factor receptors

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(**type 2**; generation of genetically modified vertebrate precursor lymphocytes for prodn. of **antibody**, antigen receptor, heterologous binding protein or fragment)

IT **Interferons**

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(.gamma.; generation of genetically modified vertebrate precursor lymphocytes for prodn. of antibody, antigen receptor, heterologous binding protein or fragment)

REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:454152 HCAPLUS

DOCUMENT NUMBER: 139:51593

TITLE: Allergens, autoantigens and their T cell epitopes for

inducing immune tolerance and for immunotherapy  
 INVENTOR(S): Larche, Mark; Ledger, Philip William  
 PATENT ASSIGNEE(S): Circassia Limited, UK  
 SOURCE: PCT Int. Appl., 114 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003047618	A2	20030612	WO 2002-GB5548	20021205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-338385P P 20011205

AB Methods for desensitizing an individual to a selected polypeptide antigen are provided. The methods entail administration of T cell epitope contg. peptides from a polypeptide antigen in such a way as to establish a tolergeneic environment, i.e., a state of hyporesponsiveness to the peptides. The selected polypeptide antigen is then administered such that the state of hyporesponsiveness and co-administration of the selected antigen are sufficient to desensitize the individual to the polypeptide antigen. Also provided are therapeutic systems useful in the methods of the invention, and the use of polypeptide antigens and peptides in the manuf. of medicaments in the methods of the invention.

IC ICM A61K039-35

CC 15-2 (Immunochemistry)

Section cross-reference(s): 63

IT Blattaria

Calliphoridae

**Cat (Felis catus)**

Cattle

Chironomidae

Coleoptera

Dermatophagoides

Diptera

**Dog (Canis familiaris)**

Embryophyta

Food

Fungi

Gerbil

Guinea pig (Cavia porcellus)

Honeybee

**Horse (Equus caballus)**

Housefly (Musca domestica)

Larva

Latex

Mammalia  
 Mite and Tick  
 Mold (fungus)  
 Mouse  
 Poaceae  
 Pollen  
 Rabbit  
 Ragweed (Ambrosia)  
 Rat  
 Sheep  
 Silkworm  
 Spider  
 Swine  
 Tenebrio molitor  
 Tephritidae  
 Tree  
 Wasp  
 (allergen; allergens, autoantigens and their T cell epitopes for inducing immune tolerance and for immunotherapy)  
 IT Allergy  
 Autoimmune disease  
 Behcet's syndrome  
 Celiac disease  
 Epitopes  
     **Immunotherapy**  
 Multiple sclerosis  
 Myasthenia gravis  
 Protein sequences  
 Rheumatoid arthritis  
 Transplant and Transplantation  
 (allergens, autoantigens and their T cell epitopes for inducing immune tolerance and for immunotherapy)  
 IT **Immunotherapy**  
 (desensitization; allergens, autoantigens and their T cell epitopes for inducing immune tolerance and for immunotherapy)  
 IT **T cell (lymphocyte)**  
 (epitopes; allergen; allergens, autoantigens and their T cell epitopes for inducing immune tolerance and for immunotherapy)  
 IT **Immunoglobulins**  
 RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (heavy chains; allergens, autoantigens and their T cell epitopes for inducing immune tolerance and for immunotherapy)

L57 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:316762 HCAPLUS

DOCUMENT NUMBER: 138:352624

TITLE: Bulk cultures of canine peripheral blood lymphocytes with solid phase anti-CD3 antibody and recombinant interleukin-2 for use in immunotherapy

AUTHOR(S): Itoh, Hiroshi; Kakuta, Tomoko; Kudo, Tetsuya; Sakonju, Iwao; Hohdatsu, Tsutomu; Ebina, Takusaburo; Takase, Katsuaki

CORPORATE SOURCE: Department of Veterinary Surgery, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori, 034-8628, Japan

SOURCE: Journal of Veterinary Medical Science (2003), 65(3),

329-333

CODEN: JVMSEQ; ISSN: 0916-7250

PUBLISHER: Japanese Society of Veterinary Science

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Interleukin (IL)-2 can induce large nos. of lymphokine-activated killer cells in peripheral blood lymphocytes (PBL), but IL-2 alone cannot induce proliferation of a large no. of canine (c) PBL. We used the solid phase anti-CD3 antibody and sol. recombinant (r) IL-2 in order to establish a large scale culture method for cPBL. The no. of lymphocytes seeded (3 .times. 10<sup>7</sup>) increased to 1 .times. 10<sup>9</sup> after incubation for 10 days. The phenotype of cultured cPBL cells (after 2 wk) showed a CD4+ or CD8+ predominant cell population. The cultured cell solns. were administered with physiol. saline i.v. to each dog. After transfusion of the cultured cells, the cPBL counts, esp. the no. of CD4+, CD8+ and CD4-CD8-(DN) cells increased significantly in the recipient dogs. Natural killer (NK) cells, .gamma..vdelta.T cells and B cells were considered to be present in the DN cell population. The NK cells and .gamma..vdelta.T cells showed no adverse reaction to the transfusion of the activated cPBL. Therefore, it is necessary to recognize the B cells present in the DN cell population by detecting CD21+ cells. In conclusion, the bulk culture system of cPBL with rIL-2 and solid phase anti-CD3 antibody may be useful for the development of novel immunotherapy in dogs.

CC 15-8 (Immunochemistry)

IT **CD4-positive T cell****CD8-positive T cell****Dog (Canis familiaris)****Immunotherapy**

Lymphocyte

(bulk cultures of canine peripheral blood lymphocytes with solid phase anti-CD3 antibody and recombinant interleukin-2 for use in immunotherapy)

IT **Interleukin 2**

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(bulk cultures of canine peripheral blood lymphocytes with solid phase anti-CD3 antibody and recombinant interleukin-2 for use in immunotherapy)

IT **Antibodies**

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(to CD3; bulk cultures of canine peripheral blood lymphocytes with solid phase anti-CD3 antibody and recombinant interleukin-2 for use in immunotherapy)

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:223756 HCAPLUS

DOCUMENT NUMBER: 138:253705

TITLE: Immunostimulatory peptide compounds for prevention and the treatment of mammalian diseases

INVENTOR(S): Papierok, Gerard; Vicens, Serge

PATENT ASSIGNEE(S): Fr.

SOURCE: Fr. Demande, 45 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1



## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2829767	A1	20030321	FR 2001-11942	20010914
WO 2003025012	A2	20030327	WO 2002-FR3134	20020913

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: FR 2001-11942 A 20010914

AB The invention discloses peptide compds. for the prevention or treatment of diseases in mammals, in particular humans, canines, felines, and equines, whose protective immunity depends on the stimulation of Th1 lymphocytes, and in particular delayed hypersensitivity. The peptide compds. comprise the sequences AARCAREGYSITDE or AASSTPSPGSGCEVDG or derivs. thereof. The peptide compds. may be used in the prodn. of medicaments, vaccines, and diagnostic reagents.

IC ICM C07K007-08  
ICS C07K014-44; G01N033-68; G01N033-531; A61K038-10; A61K039-008; A61P037-02

CC 15-2 (Immunochemistry)  
Section cross-reference(s): 1, 9

IT **Immunoglobulins**  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (G2; immunostimulatory peptide compds. for prevention and the treatment of mammalian diseases)

IT **T cell (lymphocyte)**  
(helper cell/inducer, TH1; immunostimulatory peptide compds. for prevention and the treatment of mammalian diseases)

IT **T cell (lymphocyte)**  
(helper cell/inducer, TH2; immunostimulatory peptide compds. for prevention and the treatment of mammalian diseases)

IT Canidae  
**Dog (Canis familiaris)**  
Drug delivery systems  
Equidae  
**Felidae**  
Human  
Immobilization, molecular  
Immunostimulants  
Leishmania donovani infantum  
Test kits  
Vaccines

(immunostimulatory peptide compds. for prevention and the treatment of mammalian diseases)

IT **Antibodies**  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (immunostimulatory peptide compds. for prevention and the treatment of mammalian diseases)

IT Chemotherapy

**Immunotherapy**

(treatment efficacy; immunostimulatory peptide compds. for prevention and the treatment of mammalian diseases)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:977608 HCAPLUS

DOCUMENT NUMBER: 138:54553

TITLE: Fc.epsilon.-Fc.gamma. fusion proteins for treatment of allergy and asthma

INVENTOR(S): An, Ling-Ling; Wu, Herren; Fung, Michael S. C.

PATENT ASSIGNEE(S): Tanox, Inc., USA

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002102320	A2	20021227	WO 2002-US19448	20020614
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CE, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-298710P P 20010615

AB The present invention includes Fc.epsilon. fragments conjugated with Fc.gamma. fragments, for example, Fc.epsilon.1-Hinge-Fc.epsilon.2-Fc.epsilon.3-Fc.epsilon.4-Fc.gamma.; Hinge-Fc.epsilon.2-Fc.epsilon.3-Fc.epsilon.4-Fc.gamma.; Fc.epsilon.2-Fc.epsilon.3-Fc.epsilon.4-Fc.gamma.; Fc.epsilon.3-Fc.epsilon.4-Fc.gamma.; and Fc.epsilon.3-Fc.epsilon.4-Fc.gamma., or any deriv. or peptide, which has equiv. immunol. function. The Fc.gamma. fragment may be a fragment of any of the IgG subclasses (IgG1, IgG2, IgG3, or IgG4), preferably IgG1 or IgG3, wherein the fragment binds Fc.gamma.RIIB. The present invention also includes compns. suitable for administering to a patient suffering from an allergic disease comprising the fusion protein construct in a pharmaceutical compn. including, for example, an excipient, diluant, or carrier. This treatment may be combined with anti-IgE therapy or allergen immunotherapy.

IC ICM A61K

CC 15-9 (Immunochemistry)

Section cross-reference(s): 17

IT **Immunoglobulins**

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(E, Fc.epsilon. fragment, fusion protein with Fc.gamma.;

Fc.epsilon.-Fc.gamma. fusion proteins for treatment of allergy and

- asthma)
- IT Allergy  
Asthma  
Basophil  
Cat (*Felis catus*)  
Dog (*Canis familiaris*)  
Drug allergy  
Food allergy  
Genetic vectors  
Hay fever  
Human  
Immunotherapy  
Mast cell  
Protein engineering  
(Fc.epsilon.-Fc.gamma. fusion proteins for treatment of allergy and asthma)
- IT **Immunoglobulins**  
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(G, Fc.gamma. fragment, fusion protein with Fc.epsilon.; Fc.epsilon.-Fc.gamma. fusion proteins for treatment of allergy and asthma)
- IT **Immunoglobulins**  
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(G1, Fc.gamma. fragment, fusion protein with Fc.epsilon.; Fc.epsilon.-Fc.gamma. fusion proteins for treatment of allergy and asthma)
- IT **Immunoglobulins**  
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(G3, Fc.gamma. fragment, fusion protein with Fc.epsilon.; Fc.epsilon.-Fc.gamma. fusion proteins for treatment of allergy and asthma)
- IT **Antibodies**  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(anti-IgE; Fc.epsilon.-Fc.gamma. fusion proteins for treatment of allergy and asthma)

L57 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:716299 HCAPLUS

DOCUMENT NUMBER: 137:246549

TITLE: Immunoglobulin fusion proteins that target low-affinity Fc.gamma. receptors

INVENTOR(S): Arnason, Barry G. W.; Jensen, Mark A.; White, David M.

PATENT ASSIGNEE(S): University of Chicago, USA

SOURCE: PCT Int. Appl., 139 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072608	A2	20020919	WO 2002-US7365	20020311

WO 2002072608 A3 20030508

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, ML, MR, NE, SN, TD, TG

US 2003161826 A1 20030828 US 2002-96521 20020311

PRIORITY APPLN. INFO.:

US 2001-274392P P 20010309

AB The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with Fc.gamma.R and which allow for the inclusion and targeting of a second protein domain to cells expressing Fc.gamma.R. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG1 fused to the Fc region of human IgG1. Convenient restriction sites allow for the facile introduction of addnl. N-terminal domains. In one example, the extracellular domain of human CD8.alpha. was fused with 0-4 HCH2 segments and the Fc region of IgG1. The fusion protein was shown to stimulate proliferation of interleukin-2-primed natural killer cells.

IC ICM C07K

CC 15-3 (Immunochemistry)

IT **Immunoglobulins**

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(A; fusion proteins targeting Fc.gamma. receptors using hinge-CH2 and Fc domains of)

IT **Immunoglobulins**

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(D; fusion proteins targeting Fc.gamma. receptors using hinge-CH2 and Fc domains of)

IT **Immunoglobulins**

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(E; fusion proteins targeting Fc.gamma. receptors using hinge-CH2 and Fc domains of)

IT **Immunoglobulins**

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(G1, Fc region fusion products; with hinge-CH2 multimers and other proteins)

IT **Immunoglobulins**

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(G2; fusion proteins targeting Fc.gamma. receptors using hinge-CH2 and Fc domains of)

IT **Immunoglobulins**

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(G3; fusion proteins targeting Fc.gamma. receptors using hinge-CH2 and Fc domains of)

IT **Immunoglobulins**

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(G4; fusion proteins targeting Fc.gamma. receptors using hinge-CH2 and Fc domains of)

IT **Immunoglobulins**

- RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(M; fusion proteins targeting Fc.gamma. receptors using hinge-CH2 and Fc domains of)
- IT **Immunoglobulins**  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(fragments, hinge-CH2 region fusion products; with IgG Fc domain and other proteins)
- IT **B cell (lymphocyte)**  
Macrophage  
Monocyte  
**T cell (lymphocyte)**  
(fusion proteins targeting Fc receptors of)
- IT Allergy inhibitors  
Anti-inflammatory agents  
Antiasthmatics  
Antibacterial agents  
Antirheumatic agents  
**Antitumor agents**  
Antiviral agents  
Fungicides  
**Immunotherapy**  
Protozoacides  
(fusion proteins targeting Fc.gamma. receptors)
- IT **Cat (Felis catus)**  
Cattle  
**Dog (Canis familiaris)**  
Goat  
**Horse (Equus caballus)**  
Human  
Mouse  
Rodentia  
Sheep  
Swine  
(fusion proteins targeting Fc.gamma. receptors using hinge-CH2 and Fc domains of Igs of)
- IT **Antibodies**  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(humanized, fusion products; targeting to Fc.gamma. receptors of)
- IT **Interferons**  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(.gamma.; expression by NK cells activated by fusion protein targeting Fc.gamma.RIII receptors)

L57 ANSWER 9 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:676339 HCAPLUS

DOCUMENT NUMBER: 137:210942

TITLE: Use of immunostimulatory CpG island-containing nucleic acids for treatment of diseases

INVENTOR(S): Schetter, Christian; Vollmer, Jorg

PATENT ASSIGNEE(S): Coley Pharmaceutical Group, Ltd., Bermuda

SOURCE: PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069369	A2	20020906	WO 2001-IB2888	20011210
WO 2002069369	A3	20030626		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1350262	A2	20031008	EP 2001-273824	20011210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003181406	A1	20030925	US 2002-140013	20020506
PRIORITY APPLN. INFO.:			US 2000-254341P	P 20001208
			WO 2001-IB2888	W 20011210
OTHER SOURCE(S): MARPAT 137:210942				
AB	Immunostimulatory compns. described as CpG-like nucleic acids are provided, including nucleic acids having immunostimulatory characteristics of CpG nucleic acid, despite certain substitutions of C, G, or C and G of the CpG dinucleotide. The substitutions can include, among others, exchange of methylated C for C, inosine for G, and ZpY for CpG, where Z is Cytosine or dSpacer and Y is inosine, 2-aminopurine, nebularine, or dSpacer. Also provided are methods for inducing an immune response in a subject using the CpG-like nucleic acids. The methods are useful in the treatment of a subject that has or is at risk of developing an infectious disease, allergy, asthma, cancer, anemia, thrombocytopenia, or neutropenia.			
IC	ICM H01L			
CC	1-7 (Pharmacology)			
	Section cross-reference(s): 15, 63			
IT	<b>Antitumor agents</b> (CpG islands as; use of immunostimulatory CpG island-contg. nucleic acids for treatment of diseases)			
IT	<b>B cell (lymphocyte)</b> Monocyte Mononuclear cell (leukocyte) (CpG nucleic acids in stimulation of; use of immunostimulatory CpG island-contg. nucleic acids for treatment of diseases)			
IT	<b>Cytokines</b> Interleukin 1 Interleukin 12 Interleukin 18 Interleukin 1.beta. Interleukin 2 Interleukin 3 Interleukin 4 Interleukin 6 Tumor necrosis factors			
	RL: BSU (Biological study, unclassified); BIOL (Biological study) (immunostimulatory nucleic acids in induction of; use of immunostimulatory CpG island-contg. nucleic acids for treatment of			

- diseases)
- IT **Antibodies**  
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(monoclonal, as anti-tumor agents; use of immunostimulatory CpG island-contg. nucleic acids for treatment of diseases)
- IT **T cell (lymphocyte)**  
(natural killer, stimulating activity of; use of immunostimulatory CpG island-contg. nucleic acids for treatment of diseases)
- IT Allergy inhibitors  
Anti-infective agents  
Antiasthmatics  
Antibacterial agents  
Antimicrobial agents  
Antiulcer agents  
Antiviral agents  
**Cat (Felis catus)**  
Cattle  
Chemotherapy  
Chicken (Gallus domesticus)  
**Dog (Canis familiaris)**  
Drug delivery systems  
Fish  
Fungicides  
Goat  
Guinea pig (Cavia porcellus)  
**Horse (Equus caballus)**  
Human  
Immunity  
Immunostimulants  
**Immunotherapy**  
Infection  
**Neoplasm**  
Nonhuman primate  
Parasiticides  
Rabbit  
Sheep  
Swine  
Ulcer  
(use of immunostimulatory CpG island-contg. nucleic acids for treatment of diseases)
- IT **Antitumor agents**  
(vaccines; use of immunostimulatory CpG island-contg. nucleic acids for treatment of diseases)
- IT **Interferons**  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(.alpha., immunostimulatory nucleic acids in induction of; use of immunostimulatory CpG island-contg. nucleic acids for treatment of diseases)
- IT **Interferons**  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(.gamma., immunostimulatory nucleic acids in induction of; use of immunostimulatory CpG island-contg. nucleic acids for treatment of diseases)

L57 ANSWER 10 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 2002:615861 HCAPLUS

DOCUMENT NUMBER: 137:168289  
 TITLE: Use of ragweed Ambt7 pollen allergen proteins in diagnosis and therapy  
 INVENTOR(S): Buchanan, Bob B.; Del Val, Gregorio; Frick, Oscar L.  
 PATENT ASSIGNEE(S): The Regents of the University of California, USA  
 SOURCE: PCT Int. Appl., 70 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002063012	A2	20020815	WO 2002-US3346	20020204
WO 2002063012	A3	20030313		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003170763	A1	20030911	US 2002-67484	20020204
US 2003180225	A1	20030925	US 2002-67620	20020204

PRIORITY APPLN. INFO.: US 2001-266686P P 20010205

AB A 30 kDa ragweed complete pollen ext. disulfide protein allergen has been purified from ragweed pollen, discarded in the com. defatting process of pollen. This protein is glycosylated, is water sol. and has at least one disulfide bond. IgE immunoblots with sera of ragweed sensitive patients indicated that the 30 kDa protein is a major allergen. The 30 kDa protein finds use in allergy testing and immunotherapy regimens. In addn. to the 30 kDa disulfide protein isolated from complete ragweed pollen, an 8-10 kDa ragweed complete pollen ext. disulfide protein and a 30 kDa ragweed defatted pollen ext. disulfide protein and fragments, derivs. and homologues thereof are described.

IC ICM C12N015-29  
 ICS C07K014-415; C07K016-16; A61K039-36

CC 15-9 (Immunochemistry)  
 Section cross-reference(s): 6, 11

IT **Immunoglobulins**  
 RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)  
 (E, Ambt7 pollen allergen binding to; use of ragweed Ambt7 pollen allergen proteins in diagnosis and therapy)

IT **Dog (Canis familiaris)**  
 (as disease model, for allergy; use of ragweed Ambt7 pollen allergen proteins in diagnosis and therapy)

IT **B cell (lymphocyte)**  
**T cell (lymphocyte)**  
 (epitope of Ambt7 pollen allergen; use of ragweed Ambt7 pollen allergen proteins in diagnosis and therapy)

IT **Antibodies**  
 RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical



study); BIOL (Biological study); USES (Uses)  
 (monoclonal, to ragweed Ambt7 pollen allergen; use of ragweed Ambt7  
 pollen allergen proteins in diagnosis and therapy)

IT **Antibodies**

RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical  
 study); BIOL (Biological study); USES (Uses)  
 (to ragweed Ambt7 pollen allergen; use of ragweed Ambt7 pollen allergen  
 proteins in diagnosis and therapy)

## IT Human

**Immunotherapy**

Mammalia

Pollen

Ragweed (Ambrosia)

(use of ragweed Ambt7 pollen allergen proteins in diagnosis and  
 therapy)

L57 ANSWER 11 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:314731 HCAPLUS

DOCUMENT NUMBER: 136:324056

TITLE: Fusion cells and cytokine compositions for treatment  
of disease

INVENTOR(S): Ohno, Tsuneya

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032378	A2	20020425	WO 2001-US47057	20011022
WO 2002032378	A3	20030227		
WO 2002032378	C2	20030626		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,  
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,  
 UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002168351 A1 20021114 US 2001-12134 20011022

PRIORITY APPLN. INFO.:

US 2000-242154P P 20001020

AB The present invention relates to methods and compns. for treating and  
 preventing cancer and infectious disease by administering a  
 therapeutically ED of fusion cells formed by fusion of autologous  
 dendritic cells and autologous non-dendritic cells, in combination with a  
 cytokine or other mol. which stimulates or induces a cytotoxic T cell  
 response and/or a humoral immune response. The examples discuss cancer  
 vaccines comprising interleukin 12 and dendritic cells fused with tumor  
 cells which induce tumor-specific cytotoxic T-cells. The dendritic cells  
 act as antigen-presenting cells for the tumor-assocd. antigens, thereby  
 inducing tumor-specific immune responses.

IC ICM A61K

CC 15-2 (Immunochemistry)

IT **Antitumor agents**  
(Ewing's sarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
(Kaposi's sarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
(Wilms' tumor; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
(acoustic neuroma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
(acute lymphocytic leukemia; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
(acute myelogenous leukemia; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
(adenocarcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
(astrocytoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
(basal cell carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
(bile duct carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
(bladder carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
(brain; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
(bronchi carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
(carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
(cervix; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
(chondrosarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
(chordoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
(choriocarcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
(colon carcinoma; dendritic/non-dendritic fusion cells and cytokines

for treatment of cancer and infection)

IT **Antitumor agents**  
(craniopharyngioma; dendritic/non-dendritic fusion cells and cytokines  
for treatment of cancer and infection)

IT **Antitumor agents**  
(cystadenocarcinoma; dendritic/non-dendritic fusion cells and cytokines  
for treatment of cancer and infection)

IT **T cell (lymphocyte)**  
(cytotoxic; dendritic/non-dendritic fusion cells and cytokines for  
treatment of cancer and infection)

IT Adenoviridae  
    **Adoptive immunotherapy**  
Antigen presentation  
    **Antitumor agents**  
Arbovirus  
    **CD4-positive T cell**  
    **CD8-positive T cell**  
    **Cat (Felis catus)**  
Cattle  
Cytolysis  
Cytomegalovirus  
    **Dog (Canis familiaris)**  
Fusion, biological  
Goat  
Hamster  
Hepatitis A virus  
Hepatitis B virus  
Herpesviridae  
    **Horse (Equus caballus)**  
Human  
Human T-lymphotropic virus 1  
Human T-lymphotropic virus 2  
Human coxsackievirus  
Human herpesvirus 4  
Human immunodeficiency virus 1  
Human immunodeficiency virus 2  
Infection  
Influenza virus  
Measles virus  
Monocyte  
Mouse  
Papovaviridae  
Parvovirus  
Picornaviridae  
Polycythemia vera  
Polyomavirus  
Poultry  
Poxviridae  
Rabies virus  
Rat  
Reoviridae  
Rhinovirus  
Rubella virus  
Semliki Forest virus  
Sendai virus  
Sheep  
Simian virus 40

Swine  
Togaviridae  
Vaccines  
Vaccinia virus  
    (dendritic/non-dendritic fusion cells and cytokines for treatment of  
    cancer and infection)

IT **Cytokines**  
    **Interleukin 12**  
    RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
    (Biological study); USES (Uses)  
    (dendritic/non-dendritic fusion cells and cytokines for treatment of  
    cancer and infection)

IT **Antitumor agents**  
    (embryonal carcinoma; dendritic/non-dendritic fusion cells and  
    cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
    (ependymoma; dendritic/non-dendritic fusion cells and cytokines for  
    treatment of cancer and infection)

IT **Antitumor agents**  
    (fibrosarcoma; dendritic/non-dendritic fusion cells and cytokines for  
    treatment of cancer and infection)

IT **Neoplasm**  
    Neuroglia, neoplasm  
    (fusion with dendritic cell; dendritic/non-dendritic fusion cells and  
    cytokines for treatment of cancer and infection)

IT **Antitumor agents**  
    (glioma; dendritic/non-dendritic fusion cells and cytokines for  
    treatment of cancer and infection)

IT **Antitumor agents**  
    (hemangioblastoma; dendritic/non-dendritic fusion cells and cytokines  
    for treatment of cancer and infection)

IT **Antitumor agents**  
    (hemangiosarcoma; dendritic/non-dendritic fusion cells and cytokines  
    for treatment of cancer and infection)

IT **Antitumor agents**  
    **Antitumor agents**  
    (hepatoma; dendritic/non-dendritic fusion cells and cytokines for  
    treatment of cancer and infection)

IT **Antitumor agents**  
    (leiomyosarcoma; dendritic/non-dendritic fusion cells and cytokines for  
    treatment of cancer and infection)

IT **Antitumor agents**  
    (leukemia, chronic; dendritic/non-dendritic fusion cells and cytokines  
    for treatment of cancer and infection)

IT **Antitumor agents**  
    (leukemia; dendritic/non-dendritic fusion cells and cytokines for  
    treatment of cancer and infection)

IT **Antitumor agents**  
    (liposarcoma; dendritic/non-dendritic fusion cells and cytokines for  
    treatment of cancer and infection)

IT **Antitumor agents**  
    (lung carcinoma; dendritic/non-dendritic fusion cells and cytokines for  
    treatment of cancer and infection)

IT **Antitumor agents**  
    (lung small-cell carcinoma; dendritic/non-dendritic fusion cells and  
    cytokines for treatment of cancer and infection)

IT **Antitumor agents**

- (lymphangioendotheliosarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(lymphangiosarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(lymphoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(mammary gland; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(medullary carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(medulloblastoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(melanoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(meningioma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(mesothelioma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(multiple myeloma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(myxosarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(neuroblastoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(oligodendroglioma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(osteosarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(ovary; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(pancreas; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(pinealoma inhibitors; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(prostate gland; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(renal cell carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**

- (retinoblastoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(rhabdomyosarcoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(sebaceous gland carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(seminoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(squamous cell carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(sweat gland; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(synovial membrane tumor inhibitors; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(testis; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(thyroid adenocarcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(thyroid gland papillary carcinoma; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)
- IT **Antitumor agents**  
(vaccines; dendritic/non-dendritic fusion cells and cytokines for treatment of cancer and infection)

L57 ANSWER 12 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:276421 HCAPLUS

DOCUMENT NUMBER: 136:278150

TITLE: Immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins

INVENTOR(S): Goldenberg, David M.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. 6,134,982.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002041847	A1	20020411	US 2001-921290	20010803
US 6306393	B1	20011023	US 1999-307816	19990510
PRIORITY APPLN. INFO.:			US 1998-38995	A2 19980312
			US 1999-307816	A2 19990510
			US 1997-41506P	P 19970324

- AB B-cell, T-cell, **myeloid**-cell, mast-cell, and plasma-cell disorders are significant contributors to illness and mortality in domestic animals, esp. in companion animals such as dogs and cats. These disorders include both autoimmune disorders and malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma, acute and chronic lymphocytic or **myeloid** leukemias, multiple myeloma, and mastocytomas. Antibody components that bind with B-cell or T-cell antigens or epitopes, as well as antigens or epitopes of **myeloid**, plasma and mast cells provide an effective means to treat these disorders in domestic animals. The immunotherapy uses **naked antibodies**, immunoconjugates and fusion proteins, alone or in combination with std. therapeutic regimens.
- IC ICM A61K039-395  
ICS A61K051-00
- NCL 424001490
- CC 15-3 (Immunochemistry)  
Section cross-reference(s): 1, 8
- ST immunotherapy autoimmune disease cancer antibody lymphocyte antigen; mast cell antigen antibody immunotherapy autoimmune disease cancer; **myeloid** cell antigen antibody immunotherapy autoimmune disease cancer
- IT **Antitumor agents**  
(B-cell lymphoma; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT CD antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CD126; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT **CD antigens**  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (**CD33**; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT **CD antigens**  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (**CD52**; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT **Histocompatibility antigens**  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (**HLA-DR**; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT Antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (HM1.24; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT **Cell adhesion molecules**  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (**ICAM-1 (intercellular adhesion mol. 1)**; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT **Histocompatibility antigens**

- RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(**Ia (H-2 I-region-  
assocd.)**; immunotherapy of malignant and autoimmune disorders  
in domestic animals using **naked antibodies**,  
immunoconjugates and fusion proteins)
- IT Histocompatibility antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(MHC (major histocompatibility complex), class II; immunotherapy of  
malignant and autoimmune disorders in domestic animals using  
**naked antibodies**, immunoconjugates and fusion  
proteins)
- IT Mucins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(MUC1; immunotherapy of malignant and autoimmune disorders in domestic  
animals using **naked antibodies**, immunoconjugates  
and fusion proteins)
- IT **Antigens**  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(**SSEA-1 (stage-specific  
embryonic antigen 1)**; immunotherapy of  
malignant and autoimmune disorders in domestic animals using  
**naked antibodies**, immunoconjugates and fusion  
proteins)
- IT Lymphoproliferative disorders  
(Waldenstrom's macroglobulinemia; immunotherapy of malignant and  
autoimmune disorders in domestic animals using **naked  
antibodies**, immunoconjugates and fusion proteins)
- IT **Antitumor agents**  
(acute lymphocytic leukemia; immunotherapy of malignant and autoimmune  
disorders in domestic animals using **naked antibodies**  
, immunoconjugates and fusion proteins)
- IT **Antitumor agents**  
(acute myelogenous leukemia; immunotherapy of malignant and autoimmune  
disorders in domestic animals using **naked antibodies**  
, immunoconjugates and fusion proteins)
- IT Fusion proteins (chimeric proteins)  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(antibody-contg.; immunotherapy of malignant and autoimmune disorders  
in domestic animals using **naked antibodies**,  
immunoconjugates and fusion proteins)
- IT Anemia (disease)  
(autoimmune hemolytic anemia; immunotherapy of malignant and autoimmune  
disorders in domestic animals using **naked antibodies**  
, immunoconjugates and fusion proteins)
- IT **Antibodies**  
RL: ARG (Analytical reagent use); PAC (Pharmacological activity); THU  
(Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES  
(Uses)  
(bispecific; immunotherapy of malignant and autoimmune disorders in  
domestic animals using **naked antibodies**,  
immunoconjugates and fusion proteins)
- IT **Antitumor agents**  
(chronic lymphocytic leukemia; immunotherapy of malignant and  
autoimmune disorders in domestic animals using **naked  
antibodies**, immunoconjugates and fusion proteins)
- IT **Antitumor agents**



- (chronic myelocytic leukemia; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT Dyes  
(conjugates with antibody; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT Carboranes  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(conjugates with antibody; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT Radionuclides, biological studies  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(conjugates with antibody; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT Drugs  
(immunoconjugate contg.; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT **Cytokines**  
Toxins  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(immunoconjugate contg.; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT **Drug delivery systems**  
(**immunoconjugates**, antibody-contg.; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, **immunoconjugates** and fusion proteins)
- IT **Antitumor agents**  
Autoimmune disease  
    **B cell (lymphocyte)**  
    **Cat (Felis catus)**  
Chemotherapy  
Diagnosis  
    **Dog (Canis familiaris)**  
Epitopes  
    **Horse (Equus caballus)**  
Immunomodulators  
Immunosuppressants  
    **Immunotherapy**  
    **Mast cell**  
Radiotherapy  
    **T cell (lymphocyte)**  
    (immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT **Antibodies**  
RL: ARG (Analytical reagent use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(immunotherapy of malignant and autoimmune disorders in domestic

- animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT Antigens
- CD14 (antigen)
  - CD19 (antigen)
  - CD20 (antigen)
  - CD22 (antigen)
  - CD38 (antigen)
  - CD4 (antigen)
  - CD5 (antigen)
  - CD8 (antigen)
- Haptens
- Interleukin 2 receptors
  - Invariant chain (class II antigen)
- RL: BSU (Biological study, unclassified); BIOL (Biological study) (immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT Antitumor agents
- (lymphoma; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT Mast cell
- (mastocytoma, inhibitors; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT Antitumor agents
- (mastocytoma; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT Antibodies
- RL: ARG (Analytical reagent use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
- (monoclonal; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT Antitumor agents
- (multiple myeloma; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT Antibodies
- RL: ARG (Analytical reagent use); PAC (Pharmacological activity); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
- (multispecific; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT Hematopoietic precursor cell
- (**myeloid**; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT Antitumor agents
- (non-Hodgkin's lymphoma; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT Chemicals

- (photoactive, conjugates with antibody; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT **Lymphocyte**  
(**plasma cell**; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT **Complement receptors**  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(**type 2**; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT **9001-99-4, RNase**  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(immunoconjugate contg.; immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)
- IT 50-18-0, Cyclophosphamide 50-24-8, Prednisolone 57-22-7, Vincristine 10043-66-0D, I 131, labeled immunoconjugate, biological studies 10098-91-6D, Y 90, labeled immunoconjugate, biological studies 23214-92-8, Doxorubicin  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(immunotherapy of malignant and autoimmune disorders in domestic animals using **naked antibodies**, immunoconjugates and fusion proteins)

L57 ANSWER 13 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:123216 HCAPLUS

DOCUMENT NUMBER: 136:182466

TITLE: Anti-tumor necrosis factor antibodies for diagnosing and treating obesity, immune disease, cancer, infections and others

INVENTOR(S): Giles-Komar, Jill; Knight, David M.; Heavner, George; Scallion, Bernard; Shealy, David

PATENT ASSIGNEE(S): Centocor, Inc., USA

SOURCE: PCT Int. Appl., 129 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012502	A2	20020214	WO 2001-US24785	20010807
WO 2002012502	A3	20021031		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 2003049725 A1 20030313 US 2001-920137 20010801  
 AU 2001079227 A5 20020218 AU 2001-79227 20010807  
 EP 1309691 A2 20030514 EP 2001-957489 20010807  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 BR 2001013110 A 20030916 BR 2001-13110 20010807  
 NO 2003000620 A 20030331 NO 2003-620 20030207  
 PRIORITY APPLN. INFO.:  
 US 2000-223360P P 20000807  
 US 2000-236826P P 20000929  
 US 2001-920137 A 20010801  
 WO 2001-US24785 W 20010807  
 AB The present invention relates to at least one novel anti-TNF antibodies,  
 including isolated nucleic acids that encode at least one anti-TNF  
 antibody, TNF, vectors, host cells, transgenic animals or plants, and  
 methods of making and using thereof, including therapeutic compns.,  
 methods and devices. The antibodies may combined with other drugs such as  
 TNF antagonist, antirheumatic, muscle relaxant, narcotic, NSAID,  
 analgesic, anesthetic, sedative, etc. and used for treating obesity,  
 immunol.diseases, infectious diseases, cancers and others.  
 IC ICM C12N015-13  
 ICS C07K016-24; C12N015-79; C12N005-10; A61K039-395; C07K016-42;  
 G01N033-50; G01N033-577; A61P037-00  
 CC 15-3 (Immunochemistry)  
 Section cross-reference(s): 1, 2, 3, 8, 9, 63  
 IT **Immunoglobulins**  
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);  
 PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); USES (Uses)  
 (G1; anti-TNF antibodies for diagnosing and treating cancer, infection,  
 and immunol. diseases)  
 IT **Immunoglobulins**  
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);  
 PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); USES (Uses)  
 (G; anti-TNF antibodies for diagnosing and treating cancer, infection,  
 and immunol. diseases)  
 IT Amphibia  
 Analgesics  
 Anesthetics  
 Animal cell  
 Animal tissue  
 Antiasthmatics  
 Antidepressants  
 Antimicrobial agents  
 Antipsychotics  
 Antirheumatic agents  
**Antitumor agents**  
 Autoimmune disease  
 Cardiovascular system, disease  
 DNA sequences  
 Epitopes  
 Eukaryota  
 Fish  
 Genetic vectors  
 Goat  
 Hamster  
 HeLa cell

Hormone replacement therapy

**Horse (*Equus caballus*)**

Human

Hypnotics and Sedatives

Immunosuppressants

**Immunotherapy**

Infection

Inflammation

Insecta

Labels

Medical goods

Molecular cloning

Mouse

Muscle relaxants

Narcotics

Nervous system, disease

Nervous system stimulants

Neuromuscular blocking agents

Obesity

Organ, animal

Plant cell

Primates

Prokaryote

Protein sequences

Rabbit

Radiopharmaceuticals

Rat

Reptilia

Rodentia

Sheep

(anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT **Antibodies**

**Immunoglobulins**

Nucleic acids

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);

DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); USES (Uses)

(anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT **Cytokines**

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)

(anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT **Antibodies**

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);

DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); USES (Uses)

(anti-idiotypic; anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT Lymphoma

**Multiple myeloma**

(cells; anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT **Immunoglobulins**

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);

DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(fragments; anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT **Immunoglobulins**

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(heavy chains; anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT **Immunoglobulins**

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(light chains; anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT **Antitumor agents**

**Neoplasm**

(metastasis; anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

IT **Antibodies**

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(monoclonal; anti-TNF antibodies for diagnosing and treating cancer, infection, and immunol. diseases)

L57 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:123215 HCAPLUS

DOCUMENT NUMBER: 136:182465

TITLE: Anti-.alpha.V.beta.3/.alpha.V.beta.5 dual integrin antibodies for diagnosis and therapeutic uses

INVENTOR(S): Giles-Komar, Jill; Heavner, George; Snyder, Linda; Trikha, Mohit

PATENT ASSIGNEE(S): Centocor, Inc., USA

SOURCE: PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012501	A2	20020214	WO 2001-US24784	20010807
WO 2002012501	A3	20030103		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003040044	A1	20030227	US 2001-920267	20010801
AU 2001083167	A5	20020218	AU 2001-83167	20010807

EP 1309693 A2 20030514 EP 2001-961945 20010807  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 NO 2003000621 A 20030401 NO 2003-621 20030207  
 PRIORITY APPLN. INFO.: US 2000-223363P P 20000807  
 US 2001-920267 A 20010801  
 WO 2001-US24784 W 20010807

AB The present invention relates to at least one novel anti-dual integrin antibodies, including isolated nucleic acids that encode at least one anti-dual integrin antibody, dual integrin, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compns., methods and devices. The dual integrins are .alpha.V.beta.3 and .alpha.V.beta.5. The antibodies are esp. useful for diagnosis and treatment of .alpha.V.beta.3/.alpha.V.beta.5-assocd. diseases such as (but not limited to) obesity, immunol. diseases, cardiovascular diseases, infectious diseases, malignant diseases, or neurol. diseases.

IC ICM C12N015-13  
 ICS C07K016-28; C12N015-79; C12N005-10; A61K039-395; C07K016-42;  
 G01N033-50; G01N033-577; A61P037-00

CC 15-3 (Immunochemistry)  
 Section cross-reference(s): 1, 2, 3, 8, 9, 63

IT **Immunoglobulins**  
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (G1; anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for diagnosing and treating immunol. diseases and infection and cancer)

IT **Immunoglobulins**  
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (G; anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for diagnosing and treating immunol. diseases and infection and cancer)

IT **Antibodies**  
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (anti-idiotypic; anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for diagnosing and treating immunol. diseases and infection and cancer)

IT Amphibia  
 Analgesics  
 Anesthetics  
 Animal cell  
 Animal tissue  
 Antiasthmatics  
 Antidepressants  
 Antimicrobial agents  
 Antipsychotics  
 Antirheumatic agents  
**Antitumor agents**  
 Autoimmune disease  
 Cardiovascular system, disease  
 DNA sequences  
 Epitopes  
 Eukaryota  
 Fish

Genetic vectors  
Goat  
HeLa cell  
Hormone replacement therapy  
**Horse (Equus caballus)**  
Human  
Hypnotics and Sedatives  
Immunosuppressants  
**Immunotherapy**  
Infection  
Inflammation  
Insecta  
Labels  
Medical goods  
Molecular cloning  
Mouse  
Muscle relaxants  
Narcotics  
Nervous system, disease  
Nervous system stimulants  
Neuromuscular blocking agents  
Obesity  
Organ, animal  
Plant cell  
Primates  
Prokaryote  
Protein sequences  
Rabbit  
Radiopharmaceuticals  
Rat  
Reptilia  
Rodentia  
Sheep

(anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for diagnosing and treating immunol. diseases and infection and cancer)

IT **Antibodies**

**Immunoglobulins**

Nucleic acids

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for diagnosing and treating immunol. diseases and infection and cancer)

IT **Cytokines**

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for diagnosing and treating immunol. diseases and infection and cancer)

IT **Lymphoma**

**Multiple myeloma**

(cells; anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for diagnosing and treating immunol. diseases and infection and cancer)

IT **Immunoglobulins**

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(fragments; anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for



diagnosing and treating immunol. diseases and infection and cancer)

IT **Immunoglobulins**  
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);  
 DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL  
 (Biological study); PREP (Preparation); USES (Uses)  
 (heavy chains; anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for  
 diagnosing and treating immunol. diseases and infection and cancer)

IT **Immunoglobulins**  
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);  
 DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL  
 (Biological study); PREP (Preparation); USES (Uses)  
 (light chains; anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for  
 diagnosing and treating immunol. diseases and infection and cancer)

IT **Antitumor agents**  
**Neoplasm**  
 (metastasis; anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for  
 diagnosing and treating immunol. diseases and infection and cancer)

IT **Antibodies**  
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);  
 DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL  
 (Biological study); PREP (Preparation); USES (Uses)  
 (monoclonal; anti-.alpha.V.beta.3/.alpha.V.beta.5 antibodies for  
 diagnosing and treating immunol. diseases and infection and cancer)

L57 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:636194 HCAPLUS

DOCUMENT NUMBER: 135:194468

TITLE: Hybrid cell vaccines derived by fusion of an  
 allogeneic dendritic cells and a non-dendritic cells  
 and uses in tumor and infection therapy

INVENTOR(S): Kanz, Lothar; Walden, Peter; Stuhler, Gernot

PATENT ASSIGNEE(S): Eberhard-Karls-Universitaet Tuebingen  
 Universitaetsklinikum, Germany

SOURCE: PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062902	A1	20010830	WO 2000-EP2433	20000320
W: AE, AG, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, MA, MD, MG, MN, MW, MX, NO, NZ, PL, RU, SD, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10009030	A1	20010920	DE 2000-10009030	20000227
EP 1130088	A1	20010905	EP 2000-105829	20000320
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003524020	T2	20030812	JP 2001-562676	20000320
PRIORITY APPLN. INFO.:			DE 2000-10009030 A	20000227
			US 2000-185334P P	20000228

WO 2000-EP2433 W 20000320

- AB The present invention relates to methods and compns. for treating and preventing cancer and infectious disease using hybrid cells formed by fusion of allogeneic dendritic cells and autologous non-dendritic cells which shares at least one class I MHC (major histocompatibility complex) allele. Such hybrid cells combine the vigorous alloreactivity of mature dendritic cells with the specific antigenicity of autologous tumor cells, thereby eliciting a highly specific and vigorous cytotoxic T lymphocytes (CTL) response. The invention also provides the methods for making hybrid cell vaccines and evaluating its cytotoxicity. For rapid and large-scale generation of hybrids, electrofusion is established as a two-step procedure: in the first step, tumor cells and dendritic cells (DCs) were dielectrophoretically aligned to form cell-cell conjugates; in the second step, a fusion pulse was applied, yielding 10-15% hybrid cell formation. The invention demonstrates that vaccine with tumor cell-dendritic cell hybrid results in regression of human metastatic renal cell carcinoma.
- IC ICM C12N005-16  
ICS C12N005-22; A61K039-00
- CC 15-2 (Immunochemistry)  
Section cross-reference(s): 1
- IT **Antitumor agents**  
(Ewing's sarcoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(Kaposi's sarcoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(Waldenstroem's macroglobulinemia; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(Wilms' tumor; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(acoustic neuroma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(acute lymphocytic leukemia; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(acute myelogenous leukemia; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(adenocarcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(astrocytoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**

- (basal cell carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(bile duct carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(bladder carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(bronchi carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(cervix; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(chondrosarcoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(chordoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(choriocarcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(colon carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(craniopharyngioma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(cystadenocarcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **T cell (lymphocyte)**  
(cytotoxic; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(ependymoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(fibrosarcoma; hybrid cell vaccines derived by fusion of an allogeneic

- dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(glioma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Immunoglobulins**  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(heavy chains, disease, treatment of; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(hemangiosarcoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(hepatoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT Antibacterial agents  
Antiviral agents  
    **Cat (Felis catus)**  
Cattle  
Cell fusion  
    **Dog (Canis familiaris)**  
Goat  
Hamster  
    **Horse (Equus caballus)**  
    **Immunotherapy**  
Mouse  
Parasiticides  
Poultry  
Protozoacides  
Rat  
Sheep  
Swine  
Test kits  
Transformation, genetic  
    (hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(leiomyosarcoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(leukemia; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(liposarcoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(lung carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

- IT **Antitumor agents**  
(lung small-cell carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(lymphangiosarcoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(lymphoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(mammary gland; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(medulloblastoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(melanoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(meningioma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(mesothelioma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(multiple myeloma, treatment of; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(myosarcoma inhibitors; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(neuroblastoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(oligodendroglioma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(osteosarcoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(ovary; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**

- (pancreas; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(pinealoma inhibitors; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(prostate gland; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(renal cell carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(retinoblastoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(rhabdomyosarcoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(sebaceous gland carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(seminoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(squamous cell carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(sweat gland; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(synovial membrane tumor inhibitors; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(testis; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(thyroid gland carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT **Antitumor agents**  
(thyroid gland papillary carcinoma; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)
- IT Anti-AIDS agents  
**Antitumor agents**

(vaccines; hybrid cell vaccines derived by fusion of an allogeneic dendritic cells and a non-dendritic cells and uses in tumor and infection therapy)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 16 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:617775 HCAPLUS

DOCUMENT NUMBER: 135:194459

TITLE: Kidney-specific tumor vaccine directed against kidney tumor antigen G-250

INVENTOR(S): Belldegrun, Arie; Tso, Cho-Lea

PATENT ASSIGNEE(S): The Regents of the University of California, USA

SOURCE: PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060317	A2	20010823	WO 2001-US4595	20010213
WO 2001060317	A3	20020502		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001036967	A5	20010827	AU 2001-36967	20010213
US 2002058041	A1	20020516	US 2001-783708	20010213
EP 1255554	A2	20021113	EP 2001-909186	20010213
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

PRIORITY APPLN. INFO.:

US 2000-182429P P 20000214  
US 2000-182636P P 20000215  
WO 2001-US4595 W 20010213

AB This invention provides an anti-cancer immunogenic agent(s) e.g. vaccine(s) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric mol. comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.

IC ICM A61K

CC 15-2 (Immunochemistry)

Section cross-reference(s): 63

IT **T cell (lymphocyte)**

(cytotoxic; kidney-specific tumor vaccine comprising kidney tumor antigen G-250 and GM-CSF)

IT **Cytokines**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

- (immunomodulatory; kidney-specific tumor vaccine comprising kidney tumor antigen G-250 and GM-CSF)
- IT **Adoptive immunotherapy**  
 Antigen-presenting cell  
   **Antitumor agents**  
     **B cell (lymphocyte)**  
       Blood cell  
       Canidae  
         **Cat (Felis catus)**  
           Cattle  
           DNA sequences  
           Dendritic cell  
           Epitopes  
           Eukaryote (Eukaryotae)  
           Fibroblast  
           Genetic vectors  
             **Horse (Equus caballus)**  
               Kidney, neoplasm  
               Lagomorpha  
               Lymphocyte  
               Mammal (Mammalia)  
               Molecular cloning  
               Monocyte  
               Muscle  
               Nonhuman primate  
               Protein sequences  
               Rodent  
               Swine  
             **T cell (lymphocyte)**  
               Virus vectors  
               (kidney-specific tumor vaccine comprising kidney tumor antigen G-250 and GM-CSF)
- IT **Neoplasm**  
 (metastasis, cell; kidney-specific tumor vaccine comprising kidney tumor antigen G-250 and GM-CSF)
- IT **Antitumor agents**  
 (vaccines; kidney-specific tumor vaccine comprising kidney tumor antigen G-250 and GM-CSF)

L57 ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:247187 HCAPLUS  
 DOCUMENT NUMBER: 134:275762  
 TITLE: Immunostimulatory nucleic acids  
 INVENTOR(S): Krieg, Arthur M.; Schetter, Christian; Vollmer, Jorg  
 PATENT ASSIGNEE(S): University of Iowa Research Foundation, USA; Coley  
 Pharmaceutical G.b.m.H.  
 SOURCE: PCT Int. Appl., 338 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001022972	A2	20010405	WO 2000-US26383	20000925
WO 2001022972	A3	20020117		



W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,  
 DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
 JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,  
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,  
 TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,  
 RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1221955 A2 20020717 EP 2000-965433 20000925

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL

BR 2000014236 A 20021015 BR 2000-14236 20000925

JP 2003510282 T2 20030318 JP 2001-526182 20000925

EE 200200158 A 20030616 EE 2002-158 20000925

ZA 2002001963 A 20030310 ZA 2002-1963 20020308

BG 106538 A 20021229 BG 2002-106538 20020321

NO 2002001453 A 20020527 NO 2002-1453 20020322

PRIORITY APPLN. INFO.: US 1999-156113P P 19990925  
 US 1999-156135P P 19990927  
 US 2000-227436P P 20000823  
 WO 2000-US26383 W 20000925

OTHER SOURCE(S): MARPAT 134:275762

AB The invention relates to immunostimulatory nucleic acid compns. and methods of using the compns. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/or greater than 50% C nucleotides. These immunostimulatory nucleic acids function in a similar manner to nucleic acids contg. CpG motifs. The invention also encompasses preferred CpG nucleic acids.

IC ICM A61K031-7088  
 ICS A61K039-39; A61K048-00; A61K035-12; A23L001-30; A61P037-04;  
 A61K031-7088; A61K031-00; A61K031-7088; A61K038-00; A61K031-7088;  
 A61K039-395

CC 1-7 (Pharmacology)  
 Section cross-reference(s): 15, 63

IT **Antitumor agents**  
 (Hodgkin's disease inhibitors; immunostimulatory nucleic acids)

IT **Antitumor agents**  
 (biliary tract; immunostimulatory nucleic acids)

IT **Antitumor agents**  
 (bone; immunostimulatory nucleic acids)

IT **Antitumor agents**  
 (brain; immunostimulatory nucleic acids)

IT **Antitumor agents**  
 (carcinoma; immunostimulatory nucleic acids)

IT **Antitumor agents**  
 (central nervous system; immunostimulatory nucleic acids)

IT **Antitumor agents**  
 (cervix; immunostimulatory nucleic acids)

IT **Antitumor agents**  
 (choriocarcinoma; immunostimulatory nucleic acids)

IT **Antitumor agents**  
 (colon; immunostimulatory nucleic acids)

IT **Antitumor agents**  
 (connective tissue tumor inhibitors; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(endometrium; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(esophagus; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(eye; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(hepatoma; immunostimulatory nucleic acids)

IT Allergy inhibitors

Anti-infective agents

Antiasthmatics

Antibacterial agents

Antimicrobial agents

**Antitumor agents**

Antiviral agents

**B cell (lymphocyte)**

Campylobacter

**Cat (Felis catus)**

Cattle

Cell proliferation

Chemotherapy

Chicken (Gallus domesticus)

Clostridium

Dendritic cell

**Dog (Canis familiaris)**

Drug delivery systems

Endosome

Escherichia coli

Fish

Fungicides

Genetic vectors

Goat

Haemophilus

Herpesviridae

**Horse (Equus caballus)**

Immunostimulants

**Immunotherapy**

Leukocyte

Monkey

Monocyte

Mononuclear cell (leukocyte)

Orthomyxoviridae

Parasiticides

Retroviridae

Sheep

Staphylococcus

Swine

Toxoplasma  
(immunostimulatory nucleic acids)

IT **Antibodies**

Antigens

Oligonucleotides

Phosphorothioate oligonucleotides

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(immunostimulatory nucleic acids)

IT **Interleukin 12**  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(immunostimulatory nucleic acids)

IT **Interleukin 6**  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(immunostimulatory nucleic acids)

IT **Antitumor agents**  
(intraepithelial cancer; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(kidney; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(larynx tumor inhibitors; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(lung non-small-cell carcinoma; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(lung small-cell carcinoma; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(lung; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(lymphoma; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(mammary gland; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(melanoma; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(mouth, and oral cavity; immunostimulatory nucleic acids)

IT **T cell (lymphocyte)**  
(natural killer; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(neuroblastoma; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(ovary; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(pancreas; immunostimulatory nucleic acids)

IT **B cell (lymphocyte)**  
(proliferation; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(prostate gland; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(rectum; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(sarcoma; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(skin; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(stomach; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(testis; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(thyroid; immunostimulatory nucleic acids)

IT **Antitumor agents**  
(vaccines; immunostimulatory nucleic acids)

IT **Interferons**  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(.gamma.; immunostimulatory nucleic acids)

L57 ANSWER 18 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:672376 HCAPLUS

DOCUMENT NUMBER: 129:270609

TITLE: Modified TALL-104 cells to treat cancer

INVENTOR(S): Santoli, Daniela; Rovera, Giovanni; Cesano, Alessandra

PATENT ASSIGNEE(S): The Wistar Institute of Anatomy and Biology, USA

SOURCE: U.S., 30 pp., Cont.-in-part of U.S. Ser. No. 63,188, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5820856	A	19981013	US 1995-446814	19951208
US 5272082	A	19931221	US 1992-859927	19920330
CA 2162732	AA	19941124	CA 1994-2162732	19940512
WO 9426284	A1	19941124	WO 1994-US5374	19940512
W: AU, CA, JP, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9469126	A1	19941212	AU 1994-69126	19940512
AU 694430	B2	19980723		
EP 697875	A1	19960228	EP 1994-917384	19940512
EP 697875	B1	20020116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08510131	T2	19961029	JP 1994-525736	19940512
AT 211915	E	20020215	AT 1994-917384	19940512
ES 2171169	T3	20020901	ES 1994-917384	19940512
PRIORITY APPLN. INFO.:			US 1992-859927	A2 19920330
			US 1993-63188	B2 19930514
			WO 1994-US5374	W 19940512

AB A method is provided for using modified human cytotoxic TALL-104 cell line, which is characterized by activity against tumor cells. The method comprises treating bone marrow cells of an immunosuppressed mammalian patient with the modified TALL-104 cell line and reinjecting the treated bone marrow into the patient, as a treatment of hematol. malignancies. Also provided are effective and safe methods of use of the modified cells in the manuf. of a veterinary compn. for adoptive therapy of canine lymphoma and feline leukemias.

IC ICM A01N063-00

ICS C12N005-08; C12N005-00; C12N005-22

NCL 424093700

CC 1-6 (Pharmacology)

IT **Antitumor agents****Antitumor agents**

(B-cell lymphoma; modified TALL-104 cells to treat cancer)

IT **Antitumor agents**

(acute myelogenous leukemia; modified TALL-104 cells to treat cancer)

IT **Antitumor agents**

(bladder carcinoma; modified TALL-104 cells to treat cancer)

IT **Antitumor agents**

(chronic myelocytic leukemia; modified TALL-104 cells to treat cancer)

IT **T cell (lymphocyte)**

(cytotoxic; modified TALL-104 cells to treat cancer)

IT **Antitumor agents**  
(glioblastoma; modified TALL-104 cells to treat cancer)

IT **Antitumor agents**  
**Antitumor agents**  
(hematol.; modified TALL-104 cells to treat cancer)

IT **Antitumor agents**  
(leukemia; modified TALL-104 cells to treat cancer)

IT **Antitumor agents**  
(lung carcinoma; modified TALL-104 cells to treat cancer)

IT **Antitumor agents**  
(lymphoma; modified TALL-104 cells to treat cancer)

IT **Antitumor agents**  
(mammary gland carcinoma; modified TALL-104 cells to treat cancer)

IT **Antitumor agents**  
(melanoma; modified TALL-104 cells to treat cancer)

IT **Adoptive immunotherapy**  
Antiviral agents  
**Cat (Felis catus)**  
Cytomegalovirus  
**Dog (Canis familiaris)**  
Human immunodeficiency virus  
Influenza virus  
(modified TALL-104 cells to treat cancer)

IT **Interleukin 12**  
**Interleukin 2**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(modified TALL-104 cells to treat cancer)

IT **Antitumor agents**  
(neuroblastoma; modified TALL-104 cells to treat cancer)

IT **Antitumor agents**  
(ovary carcinoma; modified TALL-104 cells to treat cancer)

IT **Antitumor agents**  
(promyelocytic leukemia; modified TALL-104 cells to treat cancer)

IT **Antitumor agents**  
(prostate carcinoma; modified TALL-104 cells to treat cancer)

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:28221 HCAPLUS

DOCUMENT NUMBER: 128:70762

TITLE: Modified cytotoxic T-cell line and compositions and methods for manufacture and use thereof in adoptive cancer therapy and against virus-infected cells

INVENTOR(S): Santoli, Daniela; Rovera, Giovanni; Cesano, Alessandra

PATENT ASSIGNEE(S): Wistar Institute of Anatomy and Biology, USA

SOURCE: U.S., 32 pp., Cont.-in-part of U.S. Ser. No. 374,289.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

US 5702702	A	19971230	US 1995-472686	19950606
US 5272082	A	19931221	US 1992-859927	19920330
CA 2162732	AA	19941124	CA 1994-2162732	19940512
ES 2171169	T3	20020901	ES 1994-917384	19940512
US 5683690	A	19971104	US 1995-374289	19950118
US 6022538	A	20000208	US 1997-847000	19970501

PRIORITY APPLN. INFO.:

	US 1992-859927	A2	19920330
	US 1993-63188	B2	19930514
	US 1995-374289	A2	19950118
	US 1995-472686	A2	19950606

AB A modified human cytotoxic T cell line is provided which is characterized by dual activity in vitro and in vivo against malignant cells and virus-infected cells. Also provided are effective and safe methods for use of the modified cells in adoptive therapy of cancer and untreatable vital diseases in MHC-mismatched recipients, and in marrow purging to achieve complete eradication of residual tumor cells from marrows of patients with leukemia and other types of cancer. Also provided are effective and safe methods for use of the cytokine stimulated, irradiated TALL-104 cells in the manuf. of a veterinary compn. for adoptive therapy of canine and feline malignancies.

IC ICM A01N063-00  
ICS C12N005-00; C12N005-08; A61K031-00

NCL 424093710

CC 1-6 (Pharmacology)  
Section cross-reference(s): 15

IT **Antitumor agents**  
(bladder carcinoma; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Interleukin 12**  
**Interleukin 2**  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(cell modification with; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **T cell (lymphocyte)**  
(cytotoxic; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Antitumor agents**  
(glioblastoma; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Antitumor agents**  
**Antitumor agents**  
(hematol.; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Antitumor agents**  
(leukemia; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Antitumor agents**  
(lung carcinoma; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Lymphocyte**  
(lymphokine-activated killer cell; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Antitumor agents**  
(lymphoma; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

IT **Antitumor agents**

- (malignant histiocytosis; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)
- IT **Antitumor agents**  
(mammary gland carcinoma; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)
- IT **Antitumor agents**  
(melanoma; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)
- IT **Adoptive immunotherapy**  
**Antitumor agents**  
Bone marrow  
**Cat (Felis catus)**  
Cytomegalovirus  
**Dog (Canis familiaris)**  
Human immunodeficiency virus  
Veterinary medicine  
(modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)
- IT **Antitumor agents**  
(neuroblastoma; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)
- IT **Antitumor agents**  
(ovary carcinoma; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)
- IT **Antitumor agents**  
(prostate carcinoma; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)
- IT **Antitumor agents**  
(solid tumor; modified cytotoxic T-cell line for adoptive cancer therapy and against virus-infected cells)

L57 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1992:424684 HCAPLUS

DOCUMENT NUMBER: 117:24684

TITLE: CD53 cell surface antigen and immunodiagnostic and therapeutic uses thereof and cloning and sequencing of many other cell surface antigens

INVENTOR(S): Seed, Brian; Aruffo, Alejandro; Amiot, Martine

PATENT ASSIGNEE(S): General Hospital Corp., USA

SOURCE: PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9201049	A2	19920123	WO 1991-US4986	19910715
WO 9201049	A3	19930930		
W: AU, CA, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9185286	A1	19920204	AU 1991-85286	19910715
AU 658370	B2	19950413		
EP 551301	A1	19930721	EP 1991-916292	19910715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06504186	T2	19940519	JP 1991-515602	19910715

JP 2001157592 A2 20010612 JP 2000-305557 19910715  
 JP 2003038179 A2 20030212 JP 2002-176484 19910715  
 PRIORITY APPLN. INFO.: US 1990-553759 A 19900713  
 JP 1991-515602 A3 19910715  
 JP 2000-305557 A3 19910715  
 WO 1991-US4986 A 19910715

AB A simple and highly efficient method for cloning cDNAs from mammalian expression libraries is based on transient expression of the antigen in mammalian host cells and phys. selection of cells expressing the antigen by adhesion to an antibody-coated substrate. Novel expression vectors allowing highly efficient construction of mammalian cDNA libraries are also disclosed. The cDNAs for CD2, LFA-3, CD28, CD7, and CD53 antigens and many others were isolated, cloned, and sequenced. CD53 and its recombinant DNA, pharmaceutical compns. comprising CD53, and immunodiagnostic assay kits comprising CD53 in sol. form are claimed.

IC ICM C12N015-00  
 ICS C07K013-00; G01N033-569; A61K037-02

CC 15-2 (Immunochemistry)  
 Section cross-reference(s): 3

IT **Canis familiaris**  
 Goat  
     **Horse**  
     Rabbit  
     Sheep  
     Swine  
     (erythrocytes of, human CD2 antigen-expressing COS cells rosetting with)

IT **Lymphocyte**  
     (B-cell, CD20 antigen of human)

IT **Immunoglobulins**  
 RL: BIOL (Biological study)  
     (G, COS cells expressing cDNA for human CDw32 antigen response to)

IT **Immunoglobulins**  
 RL: BIOL (Biological study)  
     (G, Fc.gamma.RI receptors, macrophage-specific, cloning of cDNA for and sequence of, of human)

IT **Immunoglobulins**  
 RL: PRP (Properties)  
     (G, Fc.gamma.RII receptors, cloning of cDNA for and sequence of, of human)

IT **Immunoglobulins**  
 RL: BIOL (Biological study)  
     (G, Fc.gamma.RIIA receptors, cDNA for, nucleotide sequence of, of human)

IT **Immunoglobulins**  
 RL: BIOL (Biological study)  
     (G, Fc.gamma.RIIB receptors, cDNA for, nucleotide sequence of, of human)

IT **Immunoglobulins**  
 RL: BIOL (Biological study)  
     (G, receptors, COS cells expressing cDNA for, of human)

IT **Immunoglobulins**  
 RL: BIOL (Biological study)  
     (M, COS cells expressing cDNA for human CD7 antigen response to)

IT **Immunoglobulins**  
 RL: BIOL (Biological study)  
     (M, receptors, CD7 antigen of human in relation to)



- IT **Lymphocyte**  
(T-cell, cell surface antigens of human, cloning  
and expression of cDNA for)
- IT **Therapeutics**  
(immuno-, CD53 cell surface antigen for)
- IT **Antibodies**  
RL: BIOL (Biological study)  
(monoclonal, COS cells expressing specific human cell surface antigens  
detection with)